Background: A rice-based peptide vaccine containing 7 linked human predominant T-cell epitopes (7Crp) derived from Japanese cedar (JC) pollen allergens, Cry j 1 and Cry j 2, was developed. Here, we examined the efficacy and safety of this transgenic rice in JC pollinosis patients. Methods: Transgenic rice (5, 20, and 80 g) was administered orally. We measured the T-cell proliferative activity against 7Crp, Cry j 1, and Cry j 2; the cytokine expression levels; and specific IgE and IgG4 production levels. In addition, the symptom and medication scores were monitored during the pollen season, and quality of life (QOL) was evaluated. Results: T-cell proliferative activities to Cry j 1, Cry j 2, and 7Crp were significantly depressed in a dose-dependent manner. Oral intake of 80 g transgenic rice for 20 weeks resulted in significant suppression of allergen-specific T-cell proliferation with downregulation of IL-13 and upregulation of IL-10 levels but no changes to specific IgE and IgG4 levels. The QOL symptom scores for allergic rhinitis were not significantly improved. Conclusions: Allergen-specific T-cell responses were significantly reduced by oral intake of transgenic rice in a dose-dependent manner. However, neither medication score nor QOL symptom scores could be improved during the JC pollen season with oral intake of transgenic rice for 20 weeks.
Int Arch Allergy Immunol

中文翻译：

---

口服摄入含有 7 个日本雪松花粉过敏原主要 T 细胞表位的转基因水稻的免疫学和症状影响。

背景：开发了一种含有 7 个连接的人类优势 T 细胞表位 (7Crp) 的水稻肽疫苗，这些表位源自日本雪松 (JC) 花粉过敏原 Cry j 1 和 Cry j 2。在这里，我们检查了这种转基因水稻对 JC 花粉症患者的疗效和安全性。方法：转基因水稻（5、20 和 80 g）口服给药。我们测量了针对 7Crp、Cry j 1 和 Cry j 2 的 T 细胞增殖活性；细胞因子表达水平；和特定的 IgE 和 IgG4 生产水平。此外，在花粉季节监测症状和药物评分，并评估生活质量（QOL）。结果：T 细胞对 Cry j 1、Cry j 2 和 7Crp 的增殖活性以剂量依赖性方式显着抑制。口服 80 g 转基因水稻 20 周导致过敏原特异性 T 细胞增殖的显着抑制，IL-13 下调和 IL-10 水平上调，但特异性 IgE 和 IgG4 水平没有变化。过敏性鼻炎的 QOL 症状评分没有显着改善。结论：通过口服摄入转基因水稻，过敏原特异性 T 细胞反应以剂量依赖性方式显着降低。然而，在 JC 花粉季节期间，口服摄入转基因水稻 20 周，药物评分和 QOL 症状评分均无法改善。
Int Arch 过敏免疫